Skip to main content

Table 3 Prognostic value of chemotherapy-associated lymphopenia <0.91 × 10 9 /L for OS of colorectal cancer

From: The impact of chemotherapy-associated neutrophil/ lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer

Variables Hazard ratio 95% confidence intervals P-value
Pretreatment albumin    
≥35 g/L 1.00(ref.)   
<35 g/L 1.140 0.648-2.007 0.649
Pretreatment CEA a    
<10 ng ml-1 1.00(ref.)   
≥10 ng ml-1 1. 900 1.056-3.416 0.032
Differentiation    
Well 1.00(ref.)   
Moderately 0. 865 0. 323–2.314 0.772
Low 1.097 0.311-3.871 0.885
Sex    
Male 1.00(ref.)   
Female 0.856 0.493-1.489 0.583
Age    
≤49 years 1.00(ref.)   
50-60 yeas 1.514 0.625-3.666 0.359
>60 years 1.587 0.698-3.607 0.271
Location    
Rectum 1.00(ref.)   
Left colon cancer 1.067 0.564-2.019 0.843
Right colon cancer 0.647 0.296-1.414 0.275
Stage    
II 1.00(ref.)   
III 3.641 1.980-6.697 <0.0001
Duration of lymphopenia <1.0 × 10 9L    
≤28 days 1.00(ref.)   
> 28 days 0.770 0.341-1.740 0.530
Chemotherapy-associated lymphocyte counts    
Lymphocyte counts ≥ 0.66 × 109/L 1.00(ref.)   
Lymphopenia <0.66 × 109/L 2.083 1.103-3.936 0.024
  1. a Carcinoembryonic antigen.